Twist Bioscience Corp (TWST) Stock Price Quote, News &…

Summary

Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.

Website

www.twistbioscience.com

Location

South San Francisco, CA, US

Phone800 719 0671

Employees979

CEOEmily Marine Leproust

Sector

Materials

Industry

Paper & Forest Products

IPO DateOct 31, 2018

Ask AI

Company overview

Business model, segments, and competition.

Peer comparison

Metrics vs closest competitors.

Guidance & outlook

Forward guidance and assumptions.

Bull vs bear case

Upside drivers and key risks.

Valuation snapshot

Multiples vs history and peers.

Competitive moat

Defensibility and market position.

Management track record

Leadership and capital allocation history.

How it makes money

A short diagram of the business model.

Latest Documents

Mentions in Filings

… ADI-002 for a period commencing on the first commercial sale until the longer of (i) the expiration or invalidity of the licensed patent rights or (ii) a low double digit amount of years from first commercial sale. Twist Bioscience In March 2021, the Company entered into an Antibody Discovery Agreement (the Twist Agreement) with Twist Bioscience Corporation (Twist). Under the terms of the Twist Agreement, Twist will utilize its proprietary pla …
Adicet Bio, Inc.Twist Bioscience Corp·10-Q - Quarterly report Q3·Q3 26·5 Nov
… 1 +165% $2.8B Strive ASST 2 +151% $697M OmniAb OABI 3 +146% $448M Capricor Therapeutics CAPR 4 +138% $383M Arcturus Therapeutics ARCT 5 +128% $6.2B Kodiak Sciences KOD 6 +115% $667M Chaince Digital CD 7 +111% $10.0B Twist Bioscience TWST 8 +105% $2.0B Schrödinger SDGR 9 +104% $6.0B GRAIL GRAL 10 Price return, Jul 31 to Sept 30, 2026 (August and September), about 2,000 companies Deep daily liquidity in both ASST and SATA Average daily dollar vol …
Strive, Inc.Twist Bioscience Corp·FWP - Free writing prospectus·Q4 26·13 Oct
… , sustainability and governance committee of Deckers Outdoor Corporation (NYSE), a footwear, apparel and accessories designer and distributor; on the board, audit committee, and nominating and governance committee of Twist Bioscience (NASDAQ), which manufactures synthetic DNA; and on the board and nominating and corporate governance committee of GCT Semiconductors (NYSE), a fabless designer and supplier of advanced 4G LTE, IoT and 5G semiconducto …
SYNAPTICS IncTwist Bioscience Corp·DEF 14A - Definitive proxy statement·Q1 27·15 Sep
… recovery method, the Company does not expect to recognize any income related to royalties received until the purchase price has been fully collected. No allowance for credit losses was recorded as of June 30, 2026. Twist Bioscience Royalty Purchase Agreement In October 2024, the Company entered into the Twist RPA. Under the terms of the Twist RPA, the Company acquired 50% of certain contingent payments (including royalties, milestone payments, …
LIGAND PHARMACEUTICALS INCTwist Bioscience Corp·EX-99.2 - 8-K/A - Financial Statements and Exhibits·Q3 26·2 Sep
… 2025, Mr. Kelly was Finance Director at Medac Pharma, a UK-based pharmaceutical sales company. From 2022 to 2024, he was the Head of Glasgow Finance at Chubb Insurance. From 2021 to 2022, he was a Finance Director at Twist Bioscience Corp., a manufacturer of synthetic DNA for various industries, from life sciences research to data storage technology. He was also a Senior Finance Director and European Controller at Charles River Laboratories, a co …
Coda Octopus Group, Inc.Twist Bioscience Corp·DEF 14A - Definitive proxy statement·Q4 26·17 Aug
#\*TransMedics Group, Inc. 8,957 1,200,014 \* Treace Medical Concepts, Inc. 1,785 4,141 \* Trevi Therapeutics, Inc. 2,157 22,584 \* TruBridge , Inc. 236 4,567 \*Twist Bioscience Corp. 13,996 574,816
Dimensional ETF TrustTwist Bioscience Corp·NPORT-EX - NT NPORT-P - Notification of late filing (portfolio holdings)·Q1 26·13 Aug

Key Stats

Trading

Px/Chg 1D$188.67 / +0.33%

Avg Volume1.52M

Beta1.77

Mkt Cap11.75B

FD Mkt Cap8.55B

Float

Shrs Out/Float62.27M / 59.69M

Short Float0.23%

Days to Cover5.51

Stock Repurchased$8.00K

Current Valuation

EV11.72B

EV/EBITDA-208.05

EV/Sales28.63

P/B25.82

P/S28.69

FCF Yield-0.22%

ROE-9.67%

ROA-6.51%

Current Ratio2.70

Estimates

P/E-144.55

Est P/E0.00

Est EPS-0.49

Est PEG0.00

Valuation

Metric	5Yr Avg	Aug '23	Feb '24	Jan '25	Jan '26	Oct '26
PRICE-BASED RATIOS
Price / Earnings	-77.56	-5.68	-9.25	-14.56	-91.44	-266.89
Price / Sales	30.94	6.08	7.72	9.71	25.06	106.12
Price / Book Value	8.42	1.57	3.03	6.43	5.25	25.82
Price / Free Cash Flow	-124.56	-5.47	-11.11	-43.93	-102.37	-459.90
ENTERPRISE VALUE METRICS
Enterprise Value	3,941.8	954.5	1,699.6	2,897.0	2,435.9	11,721.9
Enterprise Value / Sales	30.27	4.69	6.93	9.26	24.60	105.87
Enterprise Value / EBITDA	-91.51	-4.51	-9.76	-16.39	-116.67	-310.23
Enterprise Value / EBIT	-76.72	-4.18	-8.35	-13.92	-90.61	-266.54

Financials

Full Financials

Millions USD	5Yr CAGR (%)	Sep '21	Sep '22	Sep '23	Sep '24	Sep '25
INCOME STATEMENT
Revenue	29.9%	132.3	203.6	245.1	313.0	376.6
Gross Income	38.6%	51.7	84.2	89.7	133.3	191.0
EBITDA	-22.4%	-143.9	-211.7	-174.2	-176.7	-52.1
EBIT	-15.9%	-153.7	-228.2	-203.5	-208.1	-77.0
Net Income	-15.5%	-152.1	-217.9	-204.6	-208.7	-77.7
EPS (Diluted)	-19.8%	-3.15	-4.04	-3.60	-3.60	-1.30
BALANCE SHEET
Cash & ST Inv	-16.5%	477.9	505.0	336.4	276.4	232.4
Total Assets	-2.2%	702.1	961.4	776.4	614.3	641.9
Total Liabilities	8.6%	121.3	172.0	153.0	141.6	168.9
Total Shareholder Equity	-5%	580.8	789.4	623.4	472.7	473.0
CASH FLOW
Net Operating Cash Flow	-19.3%	-112.2	-124.4	-142.5	-64.1	-47.6
Cap Ex	86%	-27.1	-101.9	-27.8	-5.1	-28.0
Free Cash Flow	-14.2%	-139.3	-226.2	-170.3	-69.2	-75.6

Enterprise Value Bridge

Millions USD		13 Nov '26
Price (As of 13 Nov '26)		109.76
Basic Shares		62.27
Market Cap		6,834.6
Diluted Shares		62.40
Fully Diluted Shares Outstanding		62.40
Fully Diluted Market Cap		6,849.0
+Consolidated Debt		93.6
−In-the-Money Convertible Debt		—
+Capital Leases		85.0
+Operating Leases		—
−Cash & Equivalents		-117.4
−Short-term Investments		-49.4
+Total Preferred		-
−In-the-Money Convertible Preferred		—
−Investments in Unconsolidated Subs		—
+Non-Controlling Interest		-
+Pension Liabilities		—
Enterprise Value		6,810.7

Segment data

Revenue

by Products and services

Ngs Tools55%
Synthetic Genes30%
Antibody Discovery6%
Oligo Pools5%
Dna And Biopharma Libraries3%